Why MRD is a hot topic in CLL and how it should be used
Diagnosis and Initial Treatment of CLL
Peter Hillmen et al.
Understanding why CLL patients stop responding to treatment, and options for salvage therapies
Importance of Bcl-2-targeted therapies
John Gribben et al.
Trial of ibrutinib with bendamustine and rituximab in CLL: results and study design